Nautilus Biotechnology develops a single-molecule proteome analysis platform for measuring proteins and proteoforms across the human proteome. Company news centers on the Voyager™ Platform, Iterative Mapping, the Tau Proteoforms assay, early access customer activity, and collaborations that apply isoform-resolved proteomics to cancer and neurodegenerative disease research.
Updates also cover quarterly financial results, operating outlook, commercial-readiness activity, senior sales leadership, scientific conference presentations, and investor-conference participation. The company's disclosures frame Nautilus as a development-stage life sciences tools business moving its proteomics platform from validation and field evaluation toward broader customer access.
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule protein analysis platforms, has announced its participation in two upcoming investor conferences in September 2025.
The company will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on September 8th at 1:50 PM ET. Additionally, management will present at the Q3 Investor Summit Group Virtual Conference on September 16th at 1:00 PM ET, with one-on-one meetings scheduled for September 17th.
Webcasts of both presentations will be accessible through the Investors section of Nautilus's website.
Nautilus Biotechnology (NASDAQ: NAUT) reported its Q2 2025 financial results, highlighting significant progress in its single-molecule proteome analysis platform development. The company published its first scientific manuscript demonstrating the Iterative Mapping method for measuring proteoforms with unprecedented resolution. Additionally, Nautilus secured two new collaborations with research institutes focusing on Tau proteoform studies in Alzheimer's disease research.
Financial results showed operating expenses of $17.1 million, an 18% decrease from $20.8 million in Q2 2024. The company reported a net loss of $15.0 million, improved from $18.0 million year-over-year. Cash, cash equivalents, and investments stood at $179.5 million as of June 30, 2025.
Nautilus Biotechnology (NASDAQ: NAUT) has announced a strategic agreement with the Allen Institute to investigate the relationship between tau protein and Alzheimer's disease using Nautilus' Iterative Mapping technology. The collaboration aims to identify and analyze tau proteoforms from human brain tissue to better understand their role in neurodegenerative conditions.
The partnership follows Nautilus' recent preprint demonstrating their single-molecule proteomics platform's capabilities in analyzing tau proteoforms with unprecedented resolution. The technology has shown promising results in studying brain samples from both cognitively normal and impaired Alzheimer's patients, validating the platform's accuracy, sensitivity, and reproducibility.
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule protein analysis platforms, has scheduled its Q2 2025 financial results announcement for July 31, 2025, before market open.
The company will host a conference call and webcast at 5:30 AM PT / 8:30 AM ET to discuss quarterly results, business developments, and future outlook. Investors can access the live webcast through the company's website at www.nautilus.bio.
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule protein analysis platform development, has announced its participation in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will engage in a fireside chat on June 10, 2025, at 2:00 p.m. Eastern Time. Investors and interested parties can access both live and archived webcasts of the presentation through the "Investors" section on Nautilus' website at www.nautilus.bio.
Nautilus Biotechnology (NASDAQ: NAUT) has released its Q1 2025 financial results, highlighting progress in their single-molecule proteome analysis platform. CEO Sujal Patel reported positive developments in their Tau proteoform assay, with performance metrics meeting launch specifications and customer requirements.
Key financial highlights:
- Operating expenses: $18.8 million, down 13% from $21.6 million in Q1 2024
- Net loss: $16.6 million, improved from $18.7 million in Q1 2024
- Cash position: $192.8 million in cash, cash equivalents, and investments as of March 31, 2025
The company's cost reduction stems from optimized operations, timing of R&D activities, reduced stock-based compensation, and lower professional services costs. Nautilus aims to enable researchers to study Tau proteoforms in Alzheimer's and other neurodegenerative diseases throughout 2025.
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule proteome analysis platform development, has scheduled its first quarter 2025 financial results announcement for Tuesday, April 29, 2025, before market open. The company will host a conference call and webcast at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss quarterly results, business developments, and future outlook. Investors can access the live audio webcast through the company's website investor section at www.nautilus.bio.
Nautilus Biotechnology (NASDAQ: NAUT) has released its Q4 and fiscal year 2024 financial results. The company reported Q4 operating expenses of $20.0 million, unchanged from Q4 2023, while full-year operating expenses increased 7% to $81.5 million.
Key developments include:
- Net loss widened to $17.6 million in Q4 2024 and $70.8 million for full-year 2024
- Cash position stands at $206.3 million as of December 31, 2024
- Announced 16% workforce reduction to extend cash runway
- Delayed launch of proteome analysis platform to late 2026
The company expects 2025 operating expenses to be at or below 2024 levels, with current cash reserves projected to sustain operations through 2027.
Nautilus Biotechnology (NASDAQ: NAUT), a pioneer in single-molecule protein analysis platform development, has announced its participation in the TD Cowen 45th Annual Healthcare Conference. The company's management will engage in a fireside chat on March 3, 2025, at 1:50 p.m. Eastern Time.
Investors and interested parties can access both live and archived webcasts of the presentation through the 'Investors' section of www.nautilus.bio. This participation demonstrates Nautilus' continued engagement with the investment community and healthcare sector.
Nautilus Biotechnology (NASDAQ: NAUT), a company focused on single molecule protein analysis platforms, has scheduled its Q4 and full year 2024 financial results announcement for February 27, 2025, before market open. The company will host a conference call and webcast at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time on the same day to discuss results, business developments, and outlook. Investors can access the live audio webcast through the company's website.